WASOFF EVAN L (Chief Financial Officer) received a stock award from NEXIEN BIOPHARMA, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
Common stock
Shares
+250K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+250K
Price / share
—
Trade value
—
% of position
Net shares
+500K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock Direct | 4/20/2022 | A · Award | +250K | — | — | 9.1% | 2.75M | 3M |
| Common Stock Direct | 7/27/2022 | A · Award | +250K | — | — | 8.3% | 3M | 3.25M |
| Total | +500K | $0.00 | ||||||
Options to purchase common stock (right to buy)
DirectUnderlying shares
200K
Shares owned
200K
Exercise price
0.655
Expiration
—
Exercise window
—
Options to purchase common stock (right to buy)
DirectUnderlying shares
1.50M
Shares owned
1.50M
Exercise price
0.08
Expiration
—
Exercise window
—
Options to purchase common stock (right to buy)
DirectUnderlying shares
420K
Shares owned
420K
Exercise price
0.54
Expiration
—
Exercise window
—
Underlying
2.12M
Owned
2.12M
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Options to purchase common stock (right to buy) Direct | common stock | 0.655 | — | — | 200K | 200K |
| Options to purchase common stock (right to buy) Direct | common stock | 0.08 | — | — | 1.50M | 1.50M |
| Options to purchase common stock (right to buy) Direct | common stock | 0.54 | — | — | 420K | 420K |
| Total | 2.12M | 2.12M | ||||